1,Nauck and DAlessio; Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type2 diabetes with unmatched efectiveness regrading glycaemic control and body weight reduction.Cardiovascular Diabetology. (2022) 21:169. 2,德邦证券;减...
Metsera 的注射剂和口服产品线来自他们专有的包含2万多种肠道激素肽和多肽-抗体偶联物库。目前正在开发的产品包括处于I期试验中的可注射GLP-1受体激动剂、胰淀素/降钙素双受体共激动剂(DACRA,dual amylin/calcitonin receptor agonist),并与 GLP-1 受体激动剂...
GLP-1 agonist medications work bymimickingthis hormone. Inmedication terms, anagonistis amanufacturedsubstance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles)...
Eli Lilly另辟蹊径,在Dual agonist赛道上扳回一城。 诺和诺德在这个方向自然也早有布局,甚至早于Eli Lilly,他们获得了最初由Marcadia Biotech开发的GLP-1/GIP活性都优于Tirzepetide的双激动剂NNC0090-2746(RG7697),并早在2015年,就完成了与Liraglutide的头对头的Phase IIa临床试验(NCT02205528)。然而,出人意料的是...
目前正在开发的产品包括处于I期试验中的可注射GLP-1受体激动剂、胰淀素/降钙素双受体共激动剂(DACRA,dual amylin/calcitonin receptor agonist),并与 GLP-1 受体激动剂联合使用,以及GLP-1/GIP/Glucagon三重受体共激动剂(与retatrutide类似)。 · EraCal Therapeutics...
今年,在美国,第一种用于治疗2型糖尿病的双激动剂(dual agonist)药物已被批准上市。这种双激动剂药物结合了GLP-1和GIP(glucose-dependent insulinotropic polypeptide, 葡萄糖依赖性胰岛素多肽)受体激动剂,模拟了肠道激素GLP-1和GIP的作用。 参考资料: Carmelo Quarta et al. GLP-1-mediated delivery of tesaglitazar...
1.信达生物的IBI362在中国肥胖或超重人群中的多次给药剂量递增的Ib期临床研究结果(a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity)在2021年美国糖尿病协会(ADA)第81届科学会议上以线上壁报的形式发表。
[10] Frias, J. P. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020, 15, 379-394. ...
2. KUN HE, et al. 763-P - Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study. General...
[0030] 所述“GLP‑1/GIP双重激动剂(GLP‑1/GIP dual agonist)”可以与“GLP‑1/GIP受体 双重激动剂”、“GLP‑1受体和GIP受体双重激动剂”、“GLP‑1R/GIPR双重激动剂”、“双重激动 剂”,或“对GLP‑1受体和GIP受体具有活性的肽”互换使用。 [0031] 所述GLP‑1/GIP双重激动剂可以是对GLP...